TrialTranslational vision science & technology2022

Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants.

Kalliopi Stasi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.